Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

23. Dezember 2019 16:05 ET | Quelle: NewLink Genetics Corporation

NewLink Genetics Announces Exclusive Worldwide License Agreement with Ellipses Pharma for Development of and Rights to Commercialization of NLG207

AMES, Iowa, Dec. 23, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company has entered into an exclusive worldwide license agreement with Ellipses...
20. Dezember 2019 10:09 ET | Quelle: NewLink Genetics Corporation

NewLink Genetics Announces FDA Approval of Ebola Vaccine V920 (ERVEBO®)

AMES, Iowa, Dec. 20, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that, after priority review, the FDA has granted approval of ERVEBO®, or Zaire Ebola virus...
16. Dezember 2019 08:00 ET | Quelle: NewLink Genetics Corporation

NewLink Genetics Responds to Proposal from Evercel

AMES, Iowa, Dec. 16, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) (“NewLink” or the “Company”) today publicly announced its rejection of the unsolicited acquisition proposal...
12. November 2019 09:00 ET | Quelle: NewLink Genetics Corporation

NewLink Genetics Announces European Commission Grant of Conditional Marketing Approval for Ebola Vaccine V920 (ERVEBO®)

AMES, Iowa, Nov. 12, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced that Monday, November 11th, the European Commission (EC) granted a conditional marketing...
06. November 2019 08:00 ET | Quelle: NewLink Genetics Corporation

NewLink Genetics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

AMES, Iowa, Nov. 06, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced financial results for the third quarter ended September 30, 2019 and provided an update on...
30. Oktober 2019 08:30 ET | Quelle: NewLink Genetics Corporation

NewLink Genetics to Host Its Third Quarter 2019 Conference Call on November 6, 2019

AMES, Iowa, Oct. 30, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced it will host its third quarter 2019 conference call and webcast at 8:30 AM ET on Wednesday,...
21. Oktober 2019 16:30 ET | Quelle: NewLink Genetics Corporation

NewLink Genetics Announces EU Regulatory Committee (CHMP) Recommendation for Conditional Marketing Authorization for Ebola Vaccine V920 (ERVEBO®)

AMES, Iowa, Oct. 21, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that Friday, October 18th, the European Medicines Agency (EMA) Committee for Medicinal...
30. September 2019 16:35 ET | Quelle: NewLink Genetics Corporation

NewLink Genetics and Lumos Pharma Enter into Merger Agreement to Form Biopharmaceutical Company Focused on Developing Therapies to Treat Rare Diseases

-- Combined company to assume the name, Lumos Pharma, Inc. and is expected to be led by Richard J. Hawkins, current CEO of Lumos Pharma -- -- Lumos asset, LUM-201, represents first oral therapeutic...
17. September 2019 17:05 ET | Quelle: NewLink Genetics Corporation

NewLink Genetics Announces FDA Accepts Partnered Biologics License Application (BLA) and Grants Priority Review for Ebola Vaccine V920 (rVSV∆G-ZEBOV-GP)

AMES, Iowa, Sept. 17, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that the U.S. Food and Drug Administration (FDA) has accepted Merck’s Biologics License...
30. Juli 2019 08:30 ET | Quelle: NewLink Genetics Corporation

NewLink Genetics Provides Corporate Update and Reports Second Quarter 2019 Financial Results

AMES, Iowa, July 30, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) (“NewLink Genetics” or the “Company”) today announced financial results for the second quarter ended June 30,...

Vorherige Seite